Chiron Behring Gmbh & Co.

Boehringer Mannheim Gmbh

Behringwerke Aktiengesellschaft

Horst Domdey

Klaus-Dieter Hungerer

Bernhard Knapp

Bernd-Ulrich Von Specht

Christoph Kessler

Gregor Sagner

Michael Broker

Michael Br&ouml;ker

Ulrich Von Specht

Michael Duchene

Helmut Blum

The present invention relates to a hybrid protein comprising the,outer membrane protein I (OprI) which is fused with its amino terminal end to the carboxy-terminal end of a carboxy-terminal portion of the,outer membrane protein F (OprF), as well as to monoclonal or polyclonal antibodies against this hybrid protein. Both, the hybrid protein and the antibodies directed to the hybrid protein confer protection against an infection by,to laboratory animals or man.

Immunogenic hybrid protein OprF-Oprl derived from Pseudomonas aeruginosa membrane proteins

The present invention relates to a hybrid protein comprising the Pseudomonas aeruginosa outer membrane protein I (OprI) which is fused with its amino terminal end to the carboxy-terminal end of a carboxy-terminal portion of the Pseudomonas aeruginosa outer membrane protein F (OprF), as well as to monoclonal or polyclonal antibodies against this hybrid protein. Both, the hybrid protein and the antibodies directed to the hybrid protein confer protection against an infection by Pseudomonas aeruginosa to laboratory animals or man.

Immunogenic hybrid protein OprF-OprI derived from Pseudomonas aeruginosa

Simultaneous sequencing of nucleic acids

The gene for the outer membrane protein lipoprotein I (OMPI) of Pseudomonas aeruginosa ATCC 33354 has been sequenced, and the amino acid sequence has been deduced. This makes it possible to obtain this protein and immunogenic part-sequences thereof in the quantity and purity necessary for use for the preparation of vaccines.

Lipoprotein I (ompi) of pseudomonas aeruginosa

Growing community of inventors

Neuried, Germany

Horst Domdey